Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel
| Autor: | Hyungeun Lee, Hyung-Don Kim, Yoon-Koo Kang, Hyung Geun Song, Sangsoon Yoon, Min-Hee Ryu, Meesun Moon, Young-Soon Na |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty ramucirumab plus paclitaxel Gastroenterology Ramucirumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine neutrophil-to-lymphocyte ratio Internal medicine medicine In patient Neutrophil to lymphocyte ratio business.industry Hazard ratio Cancer medicine.disease myeloid-derived suppressor cells Confidence interval Oncology Paclitaxel chemistry 030220 oncology & carcinogenesis Original Article business Gastric cancer Progressive disease |
| Zdroj: | Chinese Journal of Cancer Research |
| ISSN: | 1000-9604 |
| Popis: | Objective We aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) and myeloid-derived suppressor cells (MDSCs) in gastric cancer patients treated with second-line ramucirumab plus paclitaxel. Methods A total of 116 patients with advanced or metastatic gastric cancer who receive ramucirumab plus paclitaxel were prospectively enrolled. Fresh blood samples were collected before and after treatment, and flow cytometry was performed to assess the proportions of monocytic (mMDSCs) and granulocytic MDSCs (gMDSCs). Results Median age was 58 years and 71 (61.2%) patients were male. A baseline NLR≥2.94 was associated with significantly poorer progression-free survival (PFS) and overall survival (OS) vs. an NLR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|